Key result
POTS affects up to ~14% of COVID-19 survivors, requiring tailored diagnostic and management strategies.
Why the study?
POTS has emerged as an important and challenging-to-manage component of Long-COVID, motivating a summary of literature on its mechanisms, clinical course, and management.
This contemporary review highlights the emergence of POTS as a significant sequela of COVID-19, summarizing its pathophysiological mechanisms, clinical presentation, and management strategies.
Supports vigilance for POTS in Long-COVID; leaves open optimal diagnostic criteria and management pending prospective trials.
The long-term implications of COVID-19 have garnered increasing interest in recent months, with Long-COVID impacting over 65 million individuals worldwide. Postural orthostatic tachycardia syndrome (POTS) has emerged as an important component of the Long-COVID umbrella, estimated to affect between 2 and 14% of survivors. POTS remains very challenging to diagnose and manage - this review aims to provide a brief overview of POTS as a whole and goes on to summarize the available literature pertaining to POTS in the setting of COVID-19. We provide a review of available clinical reports, outline proposed pathophysiological mechanisms and end with a brief note on management considerations.
No takes yet. Share an insight, caveat, or question.
Narasimhan et al. (2023) conducted a review in Postural Orthostatic Tachycardia Syndrome (POTS) in COVID-19. COVID-19 was evaluated. Postural orthostatic tachycardia syndrome (POTS) affects an estimated 2% to 14% of COVID-19 survivors and requires a meticulous diagnostic approach and individualized management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: